ARTICLE | Company News
Cardio3 BioSciences cardiovascular, gene/cell therapy news
January 16, 2012 8:00 AM UTC
Cardio3 received €3.1 million ($4 million) from the Walloon Region and the EU's seventh Framework Program (FP7). Cardio3 received the FP7 funding as part of a €5.9 million ($7.5 million) award from the European Commission to the Bone marrow-derived mononuclear cells for Acute Myocard Infarct (BAMI) collaborative research consortium. As part of the consortium, Cardio3 and 20 partners in 11 European countries are conducting a trial of adult stem cell therapy for the treatment of heart attack patients. ...